Zhang Dong-Mei, Pan Wei-Qing
Department of Pathogen Biology, The Second Military Medical University, Shanghai 200433, China.
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2009 Oct;27(5):390-3.
It remains an urgent need to develop effective malaria vaccine for global control of malaria. Application of high technologies such as biotechnology has facilitated the process of vaccine development for malaria. In the past 30 years, a large number of vaccine candidate antigens for malaria have been identified and some of them are currently in clinical trials. Major progress in malaria vaccine development has also been made in China. The PfCP-2.9 blood stage vaccine for malaria has entered clinical studies and some other vaccine candidates including combination malaria vaccine are currently in pre-clinical studies. The availability of various national research programs and international funding has stimulated laboratory and pre-clinical studies of malaria vaccine candidates. It remains a long-term goal to develop a safe and effective malaria vaccine to control and even eliminate the disease in the world, and many issues including malaria immunology and various types of technologies need to be addressed. However, efforts need to be continued toward the goal.
开发有效的疟疾疫苗以实现全球疟疾控制仍迫在眉睫。生物技术等高科技的应用推动了疟疾疫苗的研发进程。在过去30年里，已鉴定出大量疟疾疫苗候选抗原，其中一些目前正处于临床试验阶段。中国在疟疾疫苗研发方面也取得了重大进展。疟疾PfCP-2.9血期疫苗已进入临床研究，其他一些候选疫苗包括联合疟疾疫苗目前正处于临床前研究阶段。各种国家研究项目和国际资金的可得性刺激了疟疾疫苗候选物的实验室和临床前研究。开发一种安全有效的疟疾疫苗以在全球控制甚至消除该疾病仍是一个长期目标，包括疟疾免疫学和各类技术在内的许多问题都有待解决。然而，仍需朝着这一目标持续努力。
